Tufts CSDD Demonstrates Multi-Million-Dollar Benefits of Translational Pharmaceutics®
We are dedicated to accelerating the development of new drugs for patients around the world. We provide CRO and CDMO services including formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via our Translational Pharmaceutics® platform.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Our latest updates
News
Tufts Center for the Study of Drug Development (CSDD) today published a white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms.
Event
We will be attending Pharma Integrates 2019 on 19 November 2019 at the Leonardo Royal Hotel London Tower Bridge . Nikki Whitfield is involved in the “Accelerating early-stage productivity” panel session
Case Studies
Druggability Technologies (DRGT) is developing DRGT-46 as a novel therapy for pain. Gabor Heltovics, CEO of DRGT, explains how Quotient Sciences enabled the rapid development, clinical assessment and commercial readiness of its DRGT- 46 product using integrated services across Quotient’s network of harmonized development and manufacturing sites in the UK and US.
Scientific Posters
Presented at AAPS 2019: Phase I drug development for oncology compounds is traditionally conducted directly in patient populations. Oncology molecules have historically been cytotoxic, meaning their safety and risk:benefit profile makes them unviable for dosing in healthy subjects. While this ensures reduced nonclinical requirements, rapid access to patient data and an earlier assessment of efficacious potential, it can also present challenges. For example, patients recruited in Phase I trials typically are at end of life care and will be taking multiple co-medications and have multiple co-morbidities (e.g. liver and kidney function may vary greatly among the recruited subjects). Practically, recruiting patients into Phase I studies can also be problematic, requiring multiple clinical sites and protracted recruitment times for what would traditionally be single site, quickly recruited healthy volunteer studies.
Ask us a question
